Phase III open-label titration trial of testosterone [Natesto] twice daily patients with hypogonadism
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Acerus Pharmaceuticals
- 07 Aug 2015 New trial record
- 05 Aug 2015 Dosing is expected to be initiated within the coming weeks with trial completion anticipated by the end of first quarter of 2016, according to a Trimel Pharmaceuticals Corporation media release.
- 05 Aug 2015 According to a media release, Trimel Pharmaceuticals Corporation has completed the protocol for this trial. The investigator sites have been selected and trained, and screening for patients that meet the inclusion-exclusion criteria has started.